We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings
Read MoreHide Full Article
For the quarter ended June 2023, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) reported revenue of $3.88 billion, up 2.4% over the same period last year. EPS came in at $0.56, compared to $0.68 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +4.98%. The company delivered an EPS surprise of +3.70%, with the consensus EPS estimate being $0.54.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teva Pharmaceutical Industries Ltd. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- International Markets: $479 million compared to the $451.17 million average estimate based on three analysts. The reported number represents a change of +5.5% year over year.
Geographic Revenue- North America: $1.99 billion versus the three-analyst average estimate of $1.81 billion. The reported number represents a year-over-year change of +4.6%.
Geographic Revenue- North America- COPAXONE: $64 million compared to the $73.72 million average estimate based on three analysts. The reported number represents a change of -31.9% year over year.
Geographic Revenue- North America- BENDEKA / TREANDA: $69 million versus the three-analyst average estimate of $58.17 million. The reported number represents a year-over-year change of -16.9%.
Geographic Revenue- North America- AUSTEDO: $308 million versus $252.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +51% change.
Geographic Revenue- North America- Anda: $392 million versus the three-analyst average estimate of $328.39 million. The reported number represents a year-over-year change of +27.3%.
Geographic Revenue- Europe- COPAXONE: $60 million versus the three-analyst average estimate of $50.79 million. The reported number represents a year-over-year change of -16.7%.
Geographic Revenue- Europe- Respiratory products: $66 million versus $63.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.5% change.
Geographic Revenue- International Markets- Generic products: $394 million compared to the $385.70 million average estimate based on three analysts.
Geographic Revenue- International Markets- COPAXONE: $10 million compared to the $8.39 million average estimate based on three analysts. The reported number represents a change of +11.1% year over year.
Geographic Revenue- North America- AJOVY: $57 million versus $55 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.3% change.
Revenue- API sales to third parties: $152 million versus $158.82 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -14.1% change.
Shares of Teva Pharmaceutical Industries Ltd. have returned +10.8% over the past month versus the Zacks S&P 500 composite's +3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings
For the quarter ended June 2023, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) reported revenue of $3.88 billion, up 2.4% over the same period last year. EPS came in at $0.56, compared to $0.68 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +4.98%. The company delivered an EPS surprise of +3.70%, with the consensus EPS estimate being $0.54.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teva Pharmaceutical Industries Ltd. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- International Markets: $479 million compared to the $451.17 million average estimate based on three analysts. The reported number represents a change of +5.5% year over year.
- Geographic Revenue- North America: $1.99 billion versus the three-analyst average estimate of $1.81 billion. The reported number represents a year-over-year change of +4.6%.
- Geographic Revenue- North America- COPAXONE: $64 million compared to the $73.72 million average estimate based on three analysts. The reported number represents a change of -31.9% year over year.
- Geographic Revenue- North America- BENDEKA / TREANDA: $69 million versus the three-analyst average estimate of $58.17 million. The reported number represents a year-over-year change of -16.9%.
- Geographic Revenue- North America- AUSTEDO: $308 million versus $252.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +51% change.
- Geographic Revenue- North America- Anda: $392 million versus the three-analyst average estimate of $328.39 million. The reported number represents a year-over-year change of +27.3%.
- Geographic Revenue- Europe- COPAXONE: $60 million versus the three-analyst average estimate of $50.79 million. The reported number represents a year-over-year change of -16.7%.
- Geographic Revenue- Europe- Respiratory products: $66 million versus $63.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.5% change.
- Geographic Revenue- International Markets- Generic products: $394 million compared to the $385.70 million average estimate based on three analysts.
- Geographic Revenue- International Markets- COPAXONE: $10 million compared to the $8.39 million average estimate based on three analysts. The reported number represents a change of +11.1% year over year.
- Geographic Revenue- North America- AJOVY: $57 million versus $55 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.3% change.
- Revenue- API sales to third parties: $152 million versus $158.82 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -14.1% change.
View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>Shares of Teva Pharmaceutical Industries Ltd. have returned +10.8% over the past month versus the Zacks S&P 500 composite's +3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.